The FY2025 (Dec) proxy of Vera Therapeutics names 18 peer companies for pay. Among Vera Therapeutics and these peers, CEO pay was 7th highest of 9 and total shareholder return was 4th highest of 9.
7th highest of 9in Vera Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$5.4M$27.8M
4th highest of 9in Vera Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$17$433
Pay peer group, FY2025 (Dec) proxy
| Cogent Biosciences | ||
| Protagonist Therapeutics | ||
| Immunovant | ||
| IDEAYA Biosciences | ||
| Kymera Therapeutics | ||
| Structure Therapeutics | ||
| Spyre Therapeutics | ||
| Celldex Therapeutics | ||
| Akero Therapeutics Inc. | Not disclosed | Not disclosed |
| AnaptysBio Inc. | Not disclosed | Not disclosed |
| Arcellx Inc. | Not disclosed | Not disclosed |
| Avidity Biosciences Inc. | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals Inc. | Not disclosed | Not disclosed |
| Neumora Therapeutics Inc. | Not disclosed | Not disclosed |
| Pliant Therapeutics Inc. | Not disclosed | Not disclosed |
| Soleno Therapeutics Inc. | Not disclosed | Not disclosed |
| Summit Therapeutics | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.